The Canadian Institutes of Health Research response to antimicrobial resistance

Abstract

In this issue, read about how normal flora can now be manufactured to treat Clostridium difficile and potentially other conditions, learn how optimal vaccine use can minimize the need for antibiotics, and see how the Canadian Institutes of Health Research has been funding research on antimicrobial resistance (AMR) innovation. In the ID News section read about the use of nanotechnologies to treat HIV, tuberculosis and yeast infections, and learn about a new protein inhibitor to treat malaria. This is the last in a series of theme issues to highlight the three pillars of Canada’s Federal Action Plan on AMR: Surveillance, Stewardship and Innovation. If we all continue to work together on this three-pillar approach, the potentially devastating effects of AMR can be averted.